Holen Sie sich die Stockscreener-App
118.70
4.48%
-5.57
Vorhandelsmarkt:
118.35
-0.35
-0.29%
Schlusskurs vom Vortag:
$124.27
Offen:
$123.57
24-Stunden-Volumen:
792.04K
Relative Volume:
0.78
Marktkapitalisierung:
$6.82B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-40.10
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
-3.85%
1M Leistung:
+2.14%
6M Leistung:
+25.87%
1J Leistung:
-24.41%
1-Tages-Spanne:
$116.73
$124.00
1-Wochen-Bereich:
$116.73
$130.23
52-Wochen-Spanne:
$73.16
$161.78
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Vergleichen Sie GKOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
118.70 | 7.14B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Glaukos Corp (GKOS) Shares Gap Down to $120.3 on Jan 27 - GuruFocus
Is Glaukos Corporation a good ESG investmentMarket Sentiment Summary & Weekly High Momentum Picks - baoquankhu1.vn
Glaukos director Stapley sells $1.9m in GKOS stock By Investing.com - Investing.com Nigeria
GLAUKOS Corp Reports Insider Trading Activity in Recent Form 4 Disclosures - Meyka
Glaukos Corporation (GKOS) Stock Analysis: Navigating the Glaucoma Therapy Market with a 9% Potential Upside - DirectorsTalk Interviews
Glaukos (NYSE:GKOS) COO Sells $1,340,384.64 in Stock - MarketBeat
Glaukos (NYSE:GKOS) Director Sells $1,915,650.00 in Stock - MarketBeat
Glaukos director Stapley sells $1.9m in GKOS stock - Investing.com UK
Gilliam, Glaukos president, sells $1.34 million in GKOS stock - Investing.com UK
Gilliam, Glaukos president, sells $1.34 million in GKOS stock By Investing.com - Investing.com Nigeria
GLAUKOS Corp Executives Engage in Significant Stock Transactions - TradingView
Aug Final Week: Is Glaukos Corporation a defensive stock2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
Can Glaukos Corporation outperform under higher oil pricesPortfolio Value Report & Verified Short-Term Plans - mfd.ru
Joseph Gilliam Sells 4,502 Shares of Glaukos (NYSE:GKOS) Stock - MarketBeat
Gilliam, Glaukos Corp president, sells $561k in Gkos stock By Investing.com - Investing.com Nigeria
Gilliam, Glaukos Corp president, sells $561k in Gkos stock - Investing.com
Glaukos (GKOS) Is Up 10.0% After Reaffirming 2026 Sales Guidance And Highlighting iDose TR Momentum - simplywall.st
Maryland State Retirement & Pension System Sells 8,548 Shares of Glaukos Corporation $GKOS - MarketBeat
Why (GKOS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why Analysts See The Glaukos (GKOS) Story Shifting After The Latest Price Target Change - Yahoo Finance
Midday Stock Roundup: MDxHealth Up 9% Since Preliminary Q4, FY Results - ocbj.com
Glaukos stock price target raised to $160 from $115 at Stifel on Epioxa outlook - Investing.com UK
GKOS: Stifel Boosts Glaukos Price Target to $160 with Buy Rating - GuruFocus
Stifel Nicolaus Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock Price - MarketBeat
Glaukos stock price target raised to $160 from $115 at Stifel on Epioxa outlook By Investing.com - Investing.com South Africa
What makes Glaukos (GKOS) a good investment? - MSN
What Makes Glaukos (GKOS) a Good Investment? - Insider Monkey
Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors - TipRanks
Tuesday Insider Activity: Top Execs Make Moves at Reddit, Glaukos By Investing.com - Investing.com Nigeria
Tuesday Insider Activity: Top Execs Make Moves at Reddit, Glaukos - Investing.com
Aug Macro: Is Glaukos Corporation affected by consumer sentimentTrade Risk Summary & High Return Stock Watch Alerts - baoquankhu1.vn
Glaukos (NYSE:GKOS) CEO Sells $10,126,325.00 in Stock - MarketBeat
Glaukos (NYSE:GKOS) CEO Thomas William Burns Sells 186,945 Shares - MarketBeat
Burns, Glaukos chairman & ceo, sells $31.6 million in GKOS stock - Investing.com UK
Burns, Glaukos chairman & ceo, sells $31.6 million in GKOS stock By Investing.com - Investing.com South Africa
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 - Business Wire
Campbell & CO Investment Adviser LLC Acquires Shares of 13,588 Glaukos Corporation $GKOS - MarketBeat
How Glaukos Corporation stock performs in rate cut cyclesMarket Risk Summary & Low Volatility Stock Suggestions - bollywoodhelpline.com
EPS Watch: What hedge funds are buying ProShares Trust ProShares UltraShort FTSE China 50Share Buyback & Trade Opportunity Analysis - baoquankhu1.vn
Glaukos Sees Revenue Surge as Analysts Raise Price Targets - StocksToTrade
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Glaukos (GKOS) - The Globe and Mail
How Glaukos’ Reaffirmed 2026 Sales Guidance and iDose TR Momentum Will Impact Glaukos (GKOS) Investors - simplywall.st
Glaukos (NYSE:GKOS) Trading 7.8% HigherHere's What Happened - MarketBeat
Glaukos Surges with Strong Year-End Financials and Optimistic Future Outlook - StocksToTrade
Glaukos Reports Preliminary Q4 and 2025 Results, Reaffirms 2026 Revenue Guidance - VisionMonday.com
Needham Reiterates Buy Rating for Glaukos (GKOS) | GKOS Stock Ne - GuruFocus
Glaukos stock falls despite strong Q4 revenue beat, UBS reiterates Buy By Investing.com - Investing.com Australia
Glaukos (NYSE:GKOS) Shares Gap DownHere's What Happened - MarketBeat
Glaukos stock falls despite strong Q4 revenue beat, UBS reiterates Buy - Investing.com Canada
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):